Learn how our Opto CLD workflow can help remove the bottleneck from traditional cell line development.
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.
Read this application note to learn more about how to get early, multi-parameter assessment of clones with the Opto Assure assay series.
Learn about improved and expedited cell line development on the Beacon platform from Biogen’s Rachel Ferguson.